For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 7,485,813 | |||
| General and administrative | 4,359,663 | |||
| Total operating expenses | 11,845,476 | |||
| Loss from operations | -11,845,476 | |||
| Foreign currency transaction (loss) gain | -11,814 | |||
| Interest income, net | 270,170 | |||
| Other income | 125 | |||
| Total other income | 258,481 | |||
| Net loss before income taxes | -11,586,995 | |||
| Income tax benefit | -506,615 | |||
| Net loss applicable to common stockholders | -11,080,380 | |||
| Basic EPS | -2.14 | |||
| Diluted EPS | -2.14 | |||
| Basic Average Shares | 5,188,799 | |||
| Diluted Average Shares | 5,188,799 | |||
SOLIGENIX, INC. (SNGX)
SOLIGENIX, INC. (SNGX)